CSIMarket
 
Cellectis S a   (CLLS)
Other Ticker:  
 
 
Price: $2.4900 $-0.05 -1.969%
Day's High: $2.56 Week Perf: -4.96 %
Day's Low: $ 2.43 30 Day Perf: -12.63 %
Volume (M): 25 52 Wk High: $ 3.77
Volume (M$): $ 61 52 Wk Avg: $2.23
Open: $2.56 52 Wk Low: $0.96



 Market Capitalization (Millions $) 113
 Shares Outstanding (Millions) 46
 Employees -
 Revenues (TTM) (Millions $) 19
 Net Income (TTM) (Millions $) -114
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 2

Cellectis S A
Cellectis S.A. is a French biotechnology company focused on developing innovative immunotherapies for the treatment of cancer. The company utilizes gene editing technology, specifically TALEN (Transcription Activator-Like Effector Nucleases), to modify immune cells and create personalized chimeric antigen receptor T-cell (CAR-T) therapies.

Cellectis S.A. primarily works on allogeneic CAR-T therapies, which are made from healthy donor cells rather than a patient's own cells. This approach has the potential to create off-the-shelf treatments that can be quickly administered to patients without the need for individualized cell manufacturing. The company's lead product candidate, UCART19, is being developed for the treatment of acute lymphoblastic leukemia (ALL) and is currently in clinical trials.

Cellectis S.A. also has a subsidiary called Calyxt, which focuses on developing plant-based products with improved traits using gene editing technologies. This includes agricultural crops with enhanced nutritional value, sustainability, and resistance to diseases.

Overall, Cellectis S.A. aims to revolutionize cancer treatment by harnessing the power of gene editing to create targeted immunotherapies that could potentially provide safer and more effective treatment options for patients.


   Company Address: 8, rue de la Croix Jarry Paris 75013
   Company Phone Number: 1 81 69 16 00   Stock Exchange / Ticker: NASDAQ CLLS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Earnings announcement

Accelerating Medical Breakthroughs: Cellectis Joins Forces with AstraZeneca

Published Wed, Nov 1 2023 7:00 AM UTC



In a significant move to address the growing demand for innovative therapeutics, Cellectis, a leading biotechnology company, has entered into a strategic collaboration and investment agreements with AstraZeneca. These agreements aim to propel the development of next-generation therapies in areas with a high unmet medical need, such as oncology, immunology, and rare...






 

Cellectis S A's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com